Human HS-IL-6(High sensitive Interleukin 6) Accquant ELISA Kit

Name: Human HS-IL-6(High sensitive Interleukin 6) Accquant ELISA Kit
SKU: DEIA180
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Serum, plasma, cell culture supernatant and other biological samples

Species Reactivity

Human

Detection Method

Sandwich-ELISA

Intended Use

In vitro quantitative determination of IL-6 concentrations in serum, plasma,cell culture supernatant and other biological samples.

Contents of Kit

No.	Components	Size	Storage Conditions
1	ELISA Microplate(Dismountable)	96T (8×12)	2-8°C/-20°C
2	Lyophilized Standard	2 vials	2-8°C/-20°C
3	Biotin-labeled Antibody	120ul	2-8°C
4	HRP-Streptavidin Conjugate (SABC, 100X)	120ul	2-8°C (Avoid Direct Light)
5	TMB Substrate	10ml	2-8°C (Avoid Direct Light)
6	Sample Dilution Buffer	20ml	2-8°C
7	Antibody Dilution Buffer	10ml	2-8°C
8	SABC Dilution Buffer	10ml	2-8°C
9	Stop Solution	10ml	2-8°C
10	Wash Buffer(25X)	30ml	2-8°C
11	Plate Sealer	5 pieces

Storage

2-8°C (for sealed box), please do not freeze! See kit label for expiry date.

Performance Characteristics

Stability: Perform the stability test for the sealed kit at 37°C and 2-8°C and get relevant data.

Precision

Intra-assay Precision: samples with low, medium and high concentration are tested 20 times on same plate.
Inter-assay Precision: samples with low, medium and high concentration are tested 20 times on three different plates.

Detection Range

0.46-30pg/ml

Sensitivity

0.28pg/ml

Standard Curve

Citations

Have you cited DEIA180 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Association between IL6 gene polymorphism and the risk of chronic obstructive pulmonary disease in the north Indian population

MOLECULAR BIOLOGY RESEARCH COMMUNICATIONS

Authors: Kirtipal, Nikhil; Thakur, Hitender; Sobti, Ranbir Chander; Janmeja, Ashok Kumar

Abstract

Interleukin-6 (IL6) is encoded by the IL6 gene in human and acts as pro-inflammatory cytokine and an anti-inflammatory cytokine. Recent studies established that IL6 substantially contribute in the diagnosed of systemic inflammation for the patients suffering from lung diseases such as chronic obstructive pulmonary disease (COPD). Thereof, this work aimed to investigate the protagonist of IL6 (-174 G/C) genotypes as an essential risk factor for COPD in north Indian population. In the study, a total of 200 clinically diagnosed patients with COPD were selected against 200 patients. Statistical analysis reveleaed that there was no significant association between the IL6 -174 G/C genetic polymorphism and the risk of COPD (P>0.05).

The effects of baicalin on piglets challenged withGlaesserella parasuis

VETERINARY RESEARCH

Authors: Fu, Shulin; Yin, Ronghua; Zuo, Sanling; Liu, Jun; Zhang, Yunfei; Guo, Ling; Qiu, Yinsheng; Ye, Chun; Liu, Yu; Wu, Zhongyuan; Hou, Yongqing; Hu, Chien-An Andy

Abstract

Glaesserella parasuis(G. parasuis) causes porcine vascular inflammation and damage. Baicalin is reported to have antioxidant and anti-inflammatory functions. However, whether baicalin protects piglets againstG. parasuischallenge and the potential protective mechanism have not been investigated. Therefore, in this study, we comprehensively examined the protective efficacy of baicalin in piglets challenged withG. parasuisand the possible protective mechanism. Our results show that baicalin attenuated the release of the inflammation-related cytokines interleukin (IL) 1 beta, IL6, IL8, IL10, and tumour necrosis factor alpha (TNF-alpha) and reduced high mobility group box 1 (HMGB1) production and cell apoptosis in piglets infected withG. parasuis. Baicalin also inhibited the activation of the mitogen-activated protein kinase (MAPK) signalling pathway and protected piglets againstG. parasuischallenge. Taken together, our data suggest that baicalin could protect piglets fromG. parasuisby reducing HMGB1 release, attenuating cell apoptosis, and inhibiting MAPK signalling activation, thereby alleviating the inflammatory response induced by the bacteria. Our results suggest that baicalin has utility as a novel therapeutic drug to controlG. parasuisinfection.